Chongqing Boteng was awarded Pfizer $681 million for the second phase of a TB vaccine

2022-04-27 0 By

February 11 evening, pharmaceutical customized shares of Chongqing Boteng Shares (300363) announcement, recently,The company received a new batch of Purchase Orders from Pfizer Ireland Pharmaceuticalss, a global top 10 multinational pharmaceutical company Pfizer Inc. (hereinafter referred to as “Pfizer”).The company will provide contract custom research, development and production (CDMO) services.So far, new orders total $681 million, more than last year’s revenue.February 11, Boteng shares closed at 61.32 yuan, down 2.19%, turnover rate of 1.69%, dynamic p/E ratio of 74.83, total market value of 33.383 billion yuan.It is reported that botten’s sales to Pfizer in the last three years are as follows: revenue of 58.46 million yuan in 2019, accounting for 3.77% of the company’s operating revenue in that year;Revenue in 2020 is 103.46 million yuan, accounting for 4.99% of the operating revenue in that year;The revenue from January to September in 2021 was 151.33 million yuan, accounting for 7.46% of the current operating revenue, showing a rapid growth trend.Boteng also disclosed that the order has been effective and the delivery time is 2022.The execution of this order is expected to have a positive impact on the Company’s operating revenue and operating profit in 2022, and the Company will recognize revenue in the corresponding accounting period based on the execution of the order and revenue recognition principles.It is understood that in November last year, Botten announced that it had received a new batch of “Purchase Orders” from a large pharmaceutical company in the United States, which are customized RESEARCH, development and production (CDMO) service orders related to a small molecule innovation drug.As of the order delivery date, the company has received a total of $217 million in orders for the products in the past 12 consecutive months.At the time, the announcement did not disclose the name of the American drug company, but based on the amount of the partnership, it is presumed to be Pfizer.In 2021, Boteng is expected to achieve revenue of 3.04 billion yuan to 3.108 billion yuan, a year-on-year growth of 45%-50%;The mother’s net profit of 500 million yuan to 532 million yuan, a year-on-year increase of 54%-64%;Chongqing Zhifei Biological (300122) announced, recently learned from its wholly-owned subsidiary Anhui Zhifei Longkoma Biopharmaceutical Co., LTD., its research and development of “freeze-dried recombinant tuberculosis vaccine (AEC/BC02)” has completed phase I clinical study,Results The preliminary results showed that the vaccine had good safety and tolerability.At present, the preparation of phase ⅱ A clinical trial of the product has been completed, and the screening of subjects has begun, and the phase ⅱ A clinical trial has officially started in Hengdong County, Hengyang City, Hunan Province.On February 11, Zhifei Bio closed at 120.70 yuan, down 3.19%, turnover rate 1.30%, dynamic p/E ratio of 20.93, total market value of 193.1 billion yuan.Data show that TUBERCULOSIS is a chronic infectious disease caused by mycobacterium tuberculosis infection. According to the assessment of the World Health Organization (WHO), the population of LATENT tuberculosis infection is about 1.7 billion, accounting for about one quarter of the total population. Screening and prevention of latent tuberculosis infection population is the most important part of the WHO strategy to end TUBERCULOSIS.In 2015, the “Stop TB Strategy” was proposed, which aims to reduce the global TB incidence rate to less than 10/100,000 by 2035. It was proposed for the first time to systematically carry out LTBI detection and preventive intervention in high-risk groups to reduce the incidence of TB.It says the goal of ending TB cannot be achieved unless the problem of latent TB infection is addressed.According to introduction, freeze-dried recombinant tuberculosis vaccine (AEC/BC02) is intended to be used for the prevention of tuberculosis among people aged 18 and above with latent infection of tuberculosis bacillus, which belongs to the first class of biological products for prevention.Up to now, according to the website of the State Food and Drug Administration, there is no similar vaccine on the market at home and abroad.Zhifei bio said that if the project goes well, it will form a synergistic effect with the company’s TB matrix products (mycobacterium vaccae for injection (microcards), etc.) to provide more diversified immune options for the public.In 2021, Zhifei Bio achieved revenue of 30.637 billion yuan, with a year-on-year growth of 101.68%;Operating profit was 11.986 billion yuan, up 207.73% year on year;The net profit of the parent was 10.197 billion yuan, up 208.88%, or 6.3731 yuan per share.Upstream news chief reporter Liu Yong intern Zhang Luyu